Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension
1. In this randomized controlled trial of patients with pulmonary arterial hypertension (PAH) and high risk of mortality, sotatercept reduced ...
Tag: high-risk pulmonary arterial hypertension